Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug
The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line. Newly launched ABLi Therapeutics, aims to develop a candidate called risvodetinib as a disease-modifying therapy for Parkinson’s
CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable capsule camera and screening programs for gastrointestinal diseases, cancers and internal bleeding.
Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years.
Boston Scientific announced that it has completed its previously announced acquisition of SoniVie, for an estimated $360mn in upfront cash.
Buffalo-based Vicora secures millions in funding to continue development of a new catheter system for treating vascular diseases.
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI, Haya Therapeutics.
Nuevocor announced on Wednesday (May 7) that it completed a US$45 million Series B funding round from new and existing investors to continue it’s gene therapy work.
Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China biopharma Minghui Pharmaceutical.
California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies.
Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million series B fundraising round.
Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.